

# A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

NCT07213817

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Ipsen
<b>Enrollment</b>	114 participants

## Key Eligibility Criteria

---

### Inclusion (12)

- Participant must be ≥18 years of age, at the time of signing the informed consent.
- Participants with histologically or cytologically documented, locally advanced, or metastatic solid tumors, that relapsed or were refractory after being previously treated with standard of care therapy; or for which there is no available established therapy; or standard therapy is contraindicated or not deemed appropriate by the treating investigator.
- Participants must have measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Male and female participants Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

... and 7 more (see full listing online)

### Exclusion (19)

- Known second malignancy either progressing or requiring active treatment within the last 2 years prior to first dose of study intervention.
- Residual toxicity from prior anticancer therapy that are NCI CTCAE version 5.0 Grade 2 or higher. Stable chronic Grade 2 toxicities from previous treatments may be eligible per the judgement of investigator.
- History of major surgery within 4 weeks prior to the first dose of study intervention.
- Previous solid organ transplantation.
- Pre-existing, acute or chronic severe corneal disorders, sequelae from severe corneal disorders, or a history of corneal transplantation.

... and 14 more (see full listing online)

## Locations (12 total)

---

Yale Cancer Center-Yale University, New Haven, Connecticut, United States  
START Midwest, Grand Rapids, Michigan, United States  
Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States  
... and 9 more locations

---

<https://clinicaltrials.gov/study/NCT07213817>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).